{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:32:37Z","timestamp":1777084357262,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":270,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100008898","name":"National Space Biomedical Research Institute","doi-asserted-by":"crossref","award":["NA00404"],"award-info":[{"award-number":["NA00404"]}],"id":[{"id":"10.13039\/100008898","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1002\/jcph.391","type":"journal-article","created":{"date-parts":[[2014,9,4]],"date-time":"2014-09-04T23:30:36Z","timestamp":1409873436000},"page":"195-203","source":"Crossref","is-referenced-by-count":7,"title":["Dose escalation pharmacokinetics of intranasal scopolamine gel formulation"],"prefix":"10.1002","volume":"55","author":[{"given":"Lei","family":"Wu","sequence":"first","affiliation":[{"name":"University of Houston Houston, College of Pharmacy; Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason L.","family":"Boyd","sequence":"additional","affiliation":[{"name":"Universities Space Research Association; Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vernie","family":"Daniels","sequence":"additional","affiliation":[{"name":"Wyle Laboratories; Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Wyle Laboratories; Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana S-L.","family":"Chow","sequence":"additional","affiliation":[{"name":"University of Houston Houston, College of Pharmacy; Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Putcha","sequence":"additional","affiliation":[{"name":"NASA Johnson Space Center; Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12,5]]},"reference":[{"key":"10.1002\/jcph.391-BIB0001|jcph391-cit-0001","first-page":"705","article-title":"Pharmaceutical use by US astronauts on space shuttle missions","volume":"70","author":"Putcha","year":"1999","journal-title":"Aviat Space Environ Med"},{"key":"10.1002\/jcph.391-BIB0002|jcph391-cit-0002","first-page":"228","volume-title":"Space physiology and medicine","author":"Reschke","year":"1994"},{"issue":"6","key":"10.1002\/jcph.391-BIB0003|jcph391-cit-0003","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/j.1552-4604.1994.tb02019.x","article-title":"A retrospective study of promethazine and its failure to produce the expected incidence of sedation during space flight","volume":"34","author":"Bagian","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jcph.391-BIB0004|jcph391-cit-0004","first-page":"801","volume-title":"American hospital formulatory service 1995 Drug information","author":"AHFS","year":"1996"},{"key":"10.1002\/jcph.391-BIB0005|jcph391-cit-0005","first-page":"171","article-title":"Prevention and treatment of space sickness in shuttle-orbiter missions","volume":"50","author":"Graybiel","year":"1979","journal-title":"Aviat Space Environ Med"},{"key":"10.1002\/jcph.391-BIB0006|jcph391-cit-0006","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3181\/00379727-90-22131","article-title":"Prevention and treatment of motion sickness by intranasal medication","volume":"90","author":"Chinn","year":"1955","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1002\/jcph.391-BIB0007|jcph391-cit-0007","first-page":"131","article-title":"Evaluation of 16 anti-motion sickness drugs under controlled laboratory conditions","volume":"39","author":"Wood","year":"1968","journal-title":"Aerosp Med"},{"key":"10.1002\/jcph.391-BIB0008|jcph391-cit-0008","article-title":"Pharmacological countermeasures for space motion sickness (abstract)","author":"Dornhoffer","journal-title":"Bioastronautics Investigators' Workshop"},{"issue":"8","key":"10.1002\/jcph.391-BIB0009|jcph391-cit-0009","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1021\/js950327b","article-title":"Bioavailability of intranasal scopolamine in normal subjects","volume":"85","author":"Putcha","year":"1996","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1002\/jcph.391-BIB0010|jcph391-cit-0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2165\/00003088-200645060-00001","article-title":"Transdermal scopolamine for prevention of motion sickness: clinical pharmacokinetics and therapeutic application","volume":"45","author":"Nachum","year":"2006","journal-title":"Clin Pharm"},{"key":"10.1002\/jcph.391-BIB0011|jcph391-cit-0011","first-page":"1","article-title":"A simple noninvasive method for determining gastrointestinal function","author":"Putcha","year":"1991","journal-title":"JSC Research & Technology Annual Report"},{"key":"10.1002\/jcph.391-BIB0012|jcph391-cit-0012","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.talanta.2005.04.026","article-title":"Analysis of scopolamine and its eighteen metabolites in rat urine by liquid chromatography-tandem mass spectrometry","volume":"67","author":"Chen","year":"2005","journal-title":"Talanta"},{"key":"10.1002\/jcph.391-BIB0013|jcph391-cit-0013","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"Gibaldi","year":"1982","edition":"2"},{"key":"10.1002\/jcph.391-BIB0014|jcph391-cit-0014","first-page":"467","article-title":"Rate of absorption of scopolamine after application of Scopoderm-TTS [abstract]","volume":"66","author":"Doweck","year":"1995","journal-title":"Aviat Space Environ Med"},{"key":"10.1002\/jcph.391-BIB0015|jcph391-cit-0015","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.1981.57","article-title":"Transdermal scopolamine in the prevention of motion sickness at sea","volume":"29","author":"Price","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jcph.391-BIB0016|jcph391-cit-0016","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/03639048309044696","article-title":"Controlled release of scopolamine for prophylaxis of motion sickness","volume":"9","author":"Chandrasekaran","year":"1983","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1002\/jcph.391-BIB0017|jcph391-cit-0017","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00003495-198529030-00001","article-title":"Transdermal hyoscine (scopolamine): a preliminary review of its pharmacodynamic properties and therapeutic efficacy","volume":"29","author":"Clissold","year":"1985","journal-title":"Drugs"},{"key":"10.1002\/jcph.391-BIB0018|jcph391-cit-0018","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0165-6147(79)90073-7","article-title":"Programmed, systemic drug delivery by the transdermal route","volume":"1","author":"Shaw","year":"1980","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"10.1002\/jcph.391-BIB0019|jcph391-cit-0019","first-page":"67","article-title":"Intranasal drug delivery for systemic medications","volume":"4","author":"Chien","year":"1987","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"6","key":"10.1002\/jcph.391-BIB0020|jcph391-cit-0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1015916423156","article-title":"Pharmacokinetics and oral bioavailability of scopolamine in normal subjects","volume":"6","author":"Putcha","year":"1989","journal-title":"Pharm Res"},{"issue":"2","key":"10.1002\/jcph.391-BIB0021|jcph391-cit-0021","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0928-0987(01)00107-5","article-title":"Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo","volume":"13","author":"Klocker","year":"2001","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"10.1002\/jcph.391-BIB0022|jcph391-cit-0022","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/01.ftd.0000168293.48226.57","article-title":"Pharmacokinetics and pharmacodynamics in clinical use of scopolamine","volume":"27","author":"Renner","year":"2005","journal-title":"Therap Drug Monit"},{"issue":"8","key":"10.1002\/jcph.391-BIB0023|jcph391-cit-0023","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1023\/A:1007551927177","article-title":"Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects","volume":"17","author":"Ahmed","year":"2000","journal-title":"Pharm Res"},{"issue":"4","key":"10.1002\/jcph.391-BIB0024|jcph391-cit-0024","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3357\/ASEM.2668.2010","article-title":"The efficacy of low-dose intranasal scopolamine for motion sickness","volume":"81","author":"Simmons","year":"2010","journal-title":"Aviat Space Environ Med"},{"issue":"11","key":"10.1002\/jcph.391-BIB0025|jcph391-cit-0025","doi-asserted-by":"crossref","first-page":"523","DOI":"10.5414\/CPP38523","article-title":"Influence of grapefruit juice on scopolamine pharmacokinetics and pharmacodynamics in healthy male and female subjects","volume":"38","author":"Ebert","year":"2000","journal-title":"Int J Clin Pharmacol Therap"},{"key":"10.1002\/jcph.391-BIB0026|jcph391-cit-0026","doi-asserted-by":"crossref","first-page":"P34","DOI":"10.1016\/j.clpt.2003.11.130","article-title":"Pharmacokinetics (PK) of intraveneous scopolamine (SCP) plus physostigmine (PHY) in healthy elderly male and female volunteers","volume":"75","author":"Men","year":"2004","journal-title":"Clin Pharmacol Therap"},{"key":"10.1002\/jcph.391-BIB0027|jcph391-cit-0027","first-page":"487","article-title":"Beta-Glucuronide and sulphate conjugation of scopolamine and glycopyrrolate","volume":"28","author":"Kentala","year":"1990","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1002\/jcph.391-BIB0028|jcph391-cit-0028","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/00912700122009836","article-title":"Pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effects of scopolamine in healthy volunteers","volume":"41","author":"Ebert","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jcph.391-BIB0029|jcph391-cit-0029","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/j.1552-4604.1998.tb04812.x","article-title":"Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration","volume":"38","author":"Ebert","year":"1998","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1002\/jcph.391-BIB0030|jcph391-cit-0030","first-page":"766","article-title":"Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors","volume":"76","author":"Gil","year":"2005","journal-title":"Aviat Space Environ Med"},{"issue":"4","key":"10.1002\/jcph.391-BIB0031|jcph391-cit-0031","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5414\/CPP44172","article-title":"Plasma pharmacokinetics of desmopressin following sublingual administration: an exploratory dose-escalation study in healthy male volunteers","volume":"44","author":"Steiner","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1002\/jcph.391-BIB0032|jcph391-cit-0032","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/dia.2006.8.81","article-title":"Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: a preliminary study","volume":"8","author":"Leary","year":"2006","journal-title":"Diabetes Technol Ther"},{"issue":"11","key":"10.1002\/jcph.391-BIB0033|jcph391-cit-0033","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/009127002762491325","article-title":"Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers","volume":"42","author":"Yates","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1002\/jcph.391-BIB0034|jcph391-cit-0034","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0015-0282(97)80071-4","article-title":"Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray","volume":"67","author":"Fujimoto","year":"1997","journal-title":"Fertil Steril"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.391","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jcph.391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:03:55Z","timestamp":1657803835000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.391","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}